(Total Views: 360)
Posted On: 10/15/2024 6:01:24 PM
Post# of 154171
Kat, combo trial VRC07-523LS & PGT121.
Our LL-PLS used the LS, longer acting mutations of both. This is one LS & "regular" Mab.
Shows our FcRn authors have a mountain of data. Which from the FcRn abstract release date, the Authors could be 6-8 months further along. Getting the Abstract released took 5 months alone.
I agree these HIV angles could continue to surprise, with additional progress news.
____
For implementation, bnAbs with longer half-lives and higher potencies, which can be administered subcutaneously, could provide a long-acting option to overcome some of the current PrEP adherence challenges [24, 25].
The aim of CAPRISA 012A was to identify a subcutaneous dose of VRC07-523LS and/or PGT121 for 6-monthly dosing as long-acting PrEP in African women [21].
Study Design and Participants:
CAPRISA 012A was a randomized, double blinded, placebo-controlled, dose-escalation phase 1 trial conducted in Durban, South Africa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417124/
Our LL-PLS used the LS, longer acting mutations of both. This is one LS & "regular" Mab.
Shows our FcRn authors have a mountain of data. Which from the FcRn abstract release date, the Authors could be 6-8 months further along. Getting the Abstract released took 5 months alone.
I agree these HIV angles could continue to surprise, with additional progress news.
____
For implementation, bnAbs with longer half-lives and higher potencies, which can be administered subcutaneously, could provide a long-acting option to overcome some of the current PrEP adherence challenges [24, 25].
The aim of CAPRISA 012A was to identify a subcutaneous dose of VRC07-523LS and/or PGT121 for 6-monthly dosing as long-acting PrEP in African women [21].
Study Design and Participants:
CAPRISA 012A was a randomized, double blinded, placebo-controlled, dose-escalation phase 1 trial conducted in Durban, South Africa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417124/
(1)
(0)
